| Name | Date of listing | Issue Price | closing price | closing price | % gain loss | change over |
| 11th December | 4th December | Over week | lssue price | |||
| Navkar Corporation Limited | 9th September | 155.00 | 209.60 | 195.60 | 9.03 | 35.23 |
| Pennar Engineered Building Systems Ltd | 10th September | 178.00 | 159.00 | 161.10 | -1.18 | -10.67 |
| Shree Pushkar Chem & Fert Ltd | 10th September | 65.00 | 91.60 | 100.00 | -12.92 | 40.92 |
| Sadbhav Infrastructure Project Limited | 16th September | 103.00 | 97.50 | 101.80 | -4.17 | -5.34 |
| Prabhat Dairy Limited | 21st September | 115.00 | 138.00 | 153.80 | -13.74 | 20.00 |
| Coffee Day Enterprises Limited | 2nd November | 328.00 | 256.40 | 255.00 | 0.43 | -21.83 |
| Interglobe Aviation Limited | 10th November | 765.00 | 1035.75 | 1077.35 | -5.44 | 35.39 |
| S H Kelkar & Company Limited | 16th November | 180.00 | 216.00 | 211.70 | 2.39 | 20.00 |
Performance of Newly Listed Shares as on 11th December 2015
Alkem Laboratories Limited – Issue subscribed 44 times overall
The offer for sale from the promoter and promoter group of Alkem Laboratories limited received excellent response from the investing public. The issue which comprised of 128.53 lac shares in a price band of Rs 1020-1050 by way of offer for sale was subscribed 44.29 times overall. The anchor book had received excellent response and there were 25 anchor investors comprising of 47 entitites which were allotted 37,66,358 shares at the top end of the band of Rs 1,050.
The retail portion was subscribed 3.17 times and there were in all 6.26 lac applications received. This in fact means that the retail portion on the basis of lot size was subscribed about two times and every alternate investor would be allotted shares. The HNI portion was subscribed 129.96 times and the cost of funding at an average of 8% for 8 days would mean a cost of RsRs 239 per share. This becomes the safety net for retail investors and if the price of Alkem Laboratories falls below Rs 1,290 on listing day which is the issue price and cost of leverage, there could be pressure in the share.
Full details of the subscription are given below: –
| Bucket Size | Shares Applied for | Times oversubscribed | |
| QIB | 2510906 | 143606680 | 57.19 |
| HNI | 1883179 | 244745480 | 129.96 |
| Retail | 4394086 | 13910148 | 3.17 |
| Employees | 298913 | 199290 | 0.67 |
| Total | 9087084 | 402461598 | 44.29 |
From the above table one can see the levels of subscription in various categories. The only surprise was the employee quota which remained undersubscribed even though there was a substantial Rs 100 per share discount to the employees. In any case it was a well-received IPO.
Dr Lal Pathlabs Limited – Issue subscribed over 33 times
The offer for sale from the promoters and private equity investors of Dr Lal PAthlabs was oversubscribed 33.41 times. The company had tapped the markets with its offer for sale of 1.16 cr shares in a price band of Rs 540-550 with a discount of Rs 15 to retail investors. The company had earlier allotted 34.80 lac shares to 15 anchor investors comprising of 26 entities.
The QIB portion was subscribed 63.56 times and the HNI portion almost similar at 61.28 times. The cost of leverage based on this subscription at 8% interest for 8 days comes to Rs 59 per share. The retail portion was subscribed 4.24 times and the issue received 5.60 lac applications implying that on per lot basis the retail portion is subscribed about 2.75 times on basis of lot. This would indicate that for every 11 applicants there would be 4 successful in the retail category.
The details of subscription is given below: –
| Bucket Size | Shares Applied for | Times oversubscribed | |
| QIB | 2320000 | 147452120 | 63.56 |
| HNI | 1740000 | 106633020 | 61.28 |
| Retail | 4060000 | 17201900 | 4.24 |
| Total | 8120000 | 271287040 | 33.41 |
From the above it is clear that the issue has received good response from all categories and though the pricing was considered steep, the lack of organised players in the listed space helped. Performance post listing would be a key for the company going forward.


